StudyFinder

A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA

Recruiting
I'm interested

This study is NOT accepting healthy volunteers

Gliosarcoma, MGMT-Unmethylated Glioblastoma

Ava Athmann - ava.athmann@parknicollet.com
Elizabeth Neil
Phase II/III
0123456789
NCT04396860
See this study on ClinicalTrials.gov

Back